

This is the peer reviewed version of the following article:

Gavilán AM, Díez-Fuertes F, Sanz JC, Castellanos AM, López-Perea N, Jiménez SM, Ruiz-Sopeña C, Masa-Calles J, García-Comas L, de Ory F, Pérez-Olmeda M, Fernández-García A, Echevarría JE. **Increase of Diversity of Mumps Virus Genotype G SH Variants Circulating Among a Highly Immunized Population: Spain, 2007-2019.** J Infect Dis. 2022 Dec 28;227(1):151-160.

which has been published in final form at:

<https://doi.org/10.1093/infdis/jiac176>

1 **Title: Increase of diversity of mumps virus genotype G SH variants circulating among a**  
2 **highly immunized population: Spain, 2007-2019**

3

4 A.M. Gavilán<sup>1,7</sup>, F. Díez-Fuertes<sup>1,8</sup>, J.C. Sanz<sup>2,7</sup>, A. M. Castellanos<sup>1,7</sup>, N. López-Perea<sup>3,7</sup>, S.M.  
5 Jiménez<sup>4</sup>, C. Ruiz-Sopeña<sup>5</sup>, J. Masa-Calles<sup>3,7</sup>, L. García-Comas<sup>6</sup>, F. de Ory<sup>1,7</sup>, M. Pérez-  
6 Olmeda<sup>1,8</sup>, A. Fernández-García<sup>1,7\*</sup> and J. E. Echevarría<sup>1,7\*</sup>

7

8 1. Centro Nacional de Microbiología, Instituto de Salud Carlos III. Madrid, Spain.

9 2. Laboratorio Regional de Salud Pública de la Comunidad de Madrid. Madrid, Spain.

10 3. Centro Nacional de Epidemiología, Instituto de Salud Carlos III. Madrid, Spain.

11 4. Servicio de Microbiología. Hospital de Segovia. Segovia, Spain.

12 5. Servicio de Epidemiología. Consejería de Sanidad de Castilla y León. Valladolid, Spain.

13 6. Servicio de Epidemiología. Consejería de Sanidad de la Comunidad de Madrid. Madrid, Spain.

14 7. Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública. Madrid, Spain.

15 8. Consorcio de Investigación Biomédica en Red de Enfermedades Infecciosas. Madrid, Spain.

16

17 \*Equal contribution as co-senior authors

18 Corresponding author:

19 Aurora Fernández-García

20 Phone Number: +34 918223724

21 E-mail: [aurorafg@isciii.es](mailto:aurorafg@isciii.es)

22

23 **Running Title: Mumps diversity in immunized population**

24

1 **Abstract**

2

3 MuV caused three epidemic waves in Spain since genotype G emerged in 2005, despite high  
4 vaccination coverage. SH gene sequencing according to WHO protocols allowed the  
5 identification of seven relevant variants and 88 haplotypes. While the originally imported  
6 MuVi/Sheffield.GBR/1.05/-variant prevailed during the first two waves, it was subsequently  
7 replaced by other variants originated by either local evolution or importation, according to the  
8 additional analysis of hypervariable NCRs. The time of emergence of the MRCA of each MuV  
9 variant clade was concordant with the data of the earliest sequence. The analysis of Shannon  
10 entropy showed an accumulation of variability on six particular positions as the cause of the  
11 increase on the number of circulating SH variants. Consequently, SH gene sequencing needs to  
12 be complemented with other more variable markers for mumps surveillance immediately after  
13 the emergence of a new genotype, but the subsequent emergence of new SH variants turns it  
14 unnecessary.

15

16 **Key words:**

17 mumps, mumps virus, SH variants, genetic diversity, phylogeny, molecular epidemiology,  
18 laboratory surveillance.

19

20 **Abbreviated summary** (36 words)

21 Increase on diversity of mumps variants circulating within a highly immunized population in  
22 Spain from 2007 to 2019 improved the performance of the WHO recommended molecular  
23 tools for mumps virus surveillance based on SH gene sequencing.

24

## 1 **Introduction**

2 Mumps is a vaccine-preventable disease caused by mumps virus (MuV), which is a member of  
3 the Orthorubulavirusgenus (*Paramyxoviridae* family). The MuV virion is an enveloped particle  
4 containing a non-segmented negative strand RNA molecule of 15,384 nucleotides (nt)[1].

5 Mumps is a highly transmissible disease whose main clinical symptom is swelling of the parotid  
6 glands. Previously, nonspecific symptoms can appear such as fever, headache, malaise and  
7 anorexia. Other less frequent symptoms include orchitis, mastitis, oophoritis and pancreatitis.  
8 After infection, rare complications can arise, such as aseptic meningitis and encephalitis [2].

9 Infected people can transmit the virus through respiratory droplets from two before to five days  
10 onset of parotitis [2]. Asymptomatic and subclinical infected people can also transmit the virus.

11 Mumps vaccination was introduced into the Spanish childhood immunization schedule in  
12 combination with measles and rubella virus as a part of Measles Mumps Rubella Vaccine  
13 (MMR vaccine) in 1981 [3]. As a result of the high vaccine coverage, mumps incidence  
14 dropped from 211 cases per 100,000 inhabitants in 1982 to 3-31 cases per 100,000 inhabitants  
15 from 1997. However, in Spain, as in other countries, the virus still generates outbreaks among  
16 highly vaccinated population and causes cyclic epidemic waves that peak every 4–7 years, most  
17 recently in 1996, 2000, 2007, 2013 and 2019 [3][4]. The origins of the capacity of MuV to  
18 circulate among immunized people are not well established. The use of the Rubini vaccine  
19 strain from 1992 to 1999 in Spain, which was later withdrawn due to reduced effectiveness, has  
20 been pointed as a major cause [4]. Additional hypothetical causes include waning of vaccine-  
21 induced immunity [2] [5], incomplete cross-neutralization between heterologous mumps virus  
22 genotypes [6], and a decreased capacity of the antibodies induced by the vaccine to protect  
23 against presently circulating wild-type MuV as a result of long-term antigenic drift [7]. Despite  
24 this continuous circulation, the prevalence of severe complications and hospitalizations due to  
25 MuV have decreased significantly [4].

26 WHO recommends mumps genotyping by sequencing of the SH gene as a part of the  
27 epidemiologic surveillance system required to control the disease [8]. This molecular tool

1 enables us to identify the general patterns of viral circulation, as well as to trace the source of  
2 the outbreaks and the chains of transmission. According to this molecular method, 12 genotypes  
3 have been recognized: A, B, C (including former genotype E), D, F, G, H, I, J, K (including  
4 former genotype M), L and N [9].

5 The K genotype of mumps was the first reported to be circulating in Spain in the Basque  
6 country (Northern Spain) between 1987 and 1990 [10]. Genotype H was predominant from  
7 1996 to 2003, until it was replaced by genotype G in 2005, while genotypes A, C, D and J were  
8 reported in several isolated cases or limited outbreaks [11]. Genotype G is still predominant  
9 after 15 years. A single SH variant (MuVi/Sheffield.GBR/1.05/) of genotype G was  
10 predominant from 2005 to 2015, although cryptic strain replacement between epidemic waves  
11 was demonstrated by the use of additional molecular tools based on genomic non coding  
12 regions (NCRs) [12].

13 In the present work we show the implications for molecular surveillance of the emergence of  
14 new predominant SH variants after an increase of the genomic diversity of mumps virus  
15 circulating in Spain during the period of study from 2007 to 2019.

## 16 **Materials and Methods**

### 17 1. Samples and sequences

18 A total of 8.742 samples were tested from 2008 to 2019 at the National Center for Microbiology  
19 (CNM) as part of the activities of diagnosis and surveillance of mumps, of which 2464 were  
20 found to be positive by RT-PCR. Generally, every positive case was genotyped, except during  
21 high incidence periods, when one case per location and epidemiological week was randomly  
22 selected. The MuV genotype was investigated in 1153 of them and 1125 were genotype G,  
23 which constitutes the aim of this work, together with 121 Spanish sequences from 2007 to 2019  
24 obtained from GenBank [13].

25 The first cases of relevant emerging and re-emerging variants were selected for sequencing of  
26 hypervariable non coding regions (NCRs) together with concomitant cases of previously  
27 circulating variants of the same locations (see results).

## 2. RNA extraction, genetic amplification and sequencing

Total nucleic acids were extracted with an automatic extractor (QIASymphony, Qiagen) using a commercial kit (QIASymphony Virus/Bacteria Midi Kit (96); Qiagen). Four hundred microliters of sample were extracted to obtain 40  $\mu$ L of final eluate. The whole SH gene sequence (316 nt) was obtained from all samples according to a published protocol [14]. Genomic fragments including the NCRs located between the nucleoprotein (N) and phosphoprotein (P) coding sequences (CDSs) (N-P, 768 nt) and the Matrix protein (M) and Fusion protein (F) CDSs (M-F, 452 nt), respectively, were amplified in a subset of samples (see below), as previously described [12]. PCR-amplified products were purified by an enzymatic reaction using Illustra ExoProStar 1-Step (GE Health Care Life Science, Freiburg, Germany) and sequenced using the Sanger method with the ABI Big Dye Terminator Cycle Sequencing Kit (Applied Biosystems, Branchburg, NJ, United States) using the corresponding forward and reverse primers.

## 3. Phylogenetic analysis, identification of mutations and variant classification

Sequences were edited using BioEdit v.7.2.5 [15] and aligned with MAFFT v.7 [16]. Phylogenetic analysis were performed by the method of Maximum Likelihood (ML) using the IQ-TREE software via the webserver (W-IQ-TREE) [17], with the best evolutionary model previously selected in the model selection tool, based on the Akaike information criterion. The assessment of nodes was supported by ultrafast bootstrap approach (UFboot) [18]. Phylogenetic trees were edited using MEGA v.7 [19].

Every SH sequence was named in accordance with the WHO's standard nomenclature [8]. Haplotypes (a set of identical sequences) were identified using the phylogenetic analysis and Basic Local Alignment Search Tool (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>) [20] to identify any identical sequence in GenBank. Haplotypes were named using the name of the earliest sequence. Haplotypes which showed an extensive circulation were considered variants. The specific conditions for variant assignation were continuous detection for six months or more and/or spreading to three or more Spanish provinces.

#### 4. Phylodynamic analysis

The time of emergence of the most recent common ancestor (MRCA) of the identified variants were estimated using SH sequences with the Bayesian Markov chain Monte Carlo (MCMC) coalescent method implemented in BEAST v1.10.4. [21]. Regression of root-to-tip genetic distances against sampling time was estimated using Tempest. [22]. BEAST analysis was carried out using a SRD06 codon-based evolutionary model and an uncorrelated relaxed molecular clock model with a lognormal rate distribution and the Bayesian Skyline Plot population growth model. The coalescent model was selected over other models because it assumes that a small random sample from a large population is included in the dataset. BEAST was running for at least 100 million MCMC steps, sampling every 5,000 steps, and removing 10% as burn-in. The convergence of MCMC chains was checked using Tracer v.1.7.1 [23], ensuring that the effective sample size (ESS) values were greater than 100 for each estimated parameter. The maximum clade credibility (MCC) tree was obtained from the sampled trees using TreeAnnotator v1.10.4, then visualized and edited with FigTree v1.4.4 [24].

#### 5. Shannon entropy analysis

Nucleotide variability was measured as entropy using the Shannon entropy-two tool (<https://www.hiv.lanl.gov/content/sequence/ENTROPY/entropy.html>) [25] looking for the difference in entropies between two MuV SH gene alignments in each position. The first alignment included sequences from the 2010-2015 epidemic wave and was used as background. The second one collected sequences from the 2016-2019 epidemic wave and was used as query. Shannon entropy score was calculated by summing the individual values of each position.

#### 6. GenBank Accession Numbers

The sequences obtained in this study have been deposited in GenBank under accession numbers MN436853-MN437318, MN308288-MN308363, MN489001-MN489004, MN567307-MN567478, MT906866-MT907264, MT919088-MT919099, MT858762-MT858792, MT670354-MT670376, MT26985-MT27001, MW044679-MW044695 and MW657773-MW657788.

## 7. Ethics statement

The samples used in this work were obtained in the context of the Mumps Microbiological Surveillance Programme of the CNM and used in accordance with the requirements of Spanish biomedical research law (Ley 14/2007 de Investigación Biomédica). The protocol was approved by the Comité de Ética de la Investigación del Instituto de Salud Carlos III (approval no. Reference code: CEI PI 35–2015).

## **Results**

An ML phylogenetic analysis was made with all the available MuV SH Spanish sequences from genotype G (1246) during the period of study, using the generalized time-reversible (GTR) as an evolutionary model (data not shown). In total, 88 haplotypes were identified from 2007 to 2019 (supplementary table). Seven of these haplotypes, comprising 1072 sequences (86.0%), met the criteria to be considered variants. Four hundred thirty-seven sequences (35.0%) belonged to the previously described MuVi/Sheffield.GBR/1.05/ variant (EU597478) [9].

The earliest sequence of each haplotype was used to construct an ML tree using the GTR as evolutionary model (figure 1). Most of the haplotypes were from the same genetic lineage and related to MuVi/Sheffield.GBR/1.05/, according to the topology of the phylogenetic tree (figure 1) and the nt differences (supplementary table). Six variants grouped into clades with their related haplotypes, sharing characteristic mutations in the SH sequences: MuVs/NewYork.USA/45.15/ (C248T); MuVs/Avila.ESP/11.16/ (A226T) and its derived variant MuVs/Madrid.ESP/50.16/2 subclade (A226T, T247C); MuVs/Avila.ESP/51.18/ (C13A); MuVs/Salamanca.ESP/24.19/ (T100C); MuVs/New\_Jersey.USA/20.10/ (C67T). The only exception was a sequence (MuV/Segovia. ESP/39.19/2) of the MuVs/New\_Jersey.USA/20.10/ clade, which also showed the characteristic mutation of the MuVs/Tarragona.ESP/20.11/ haplotype (G159T). Most of the haplotypes showed one to three mutations regarding the MuVi/Sheffield.GBR/1.05/ variant. Nine haplotypes had four or more mutations, two of which were grouped into variant clades: MuVs/Guadalajara.ESP/22.19/ (11 nt differences), which shares the C13A mutation with MuVs/Avila.ESP/51.18/, and

1 MuVs/Soria.ESP/48.19/ (4 nt differences), which shows the T100C mutation characteristic of  
2 the MuVs/Salamanca.ESP/24.19/ variant.

3 A total of 44 out of 88 (50%) of the haplotypes showed non-synonymous changes. Most of them  
4 have single amino acid mutation, however nine of them accumulate more than three. Three  
5 cases out of 1246 (0.24%) contained sequences of abnormal length. Two of them lost a stop  
6 codon and extended nineteen positions to reach a total of 76 amino acids instead of 57. Another  
7 one lost the final thirteen amino acids showing an SH sequence of 44 amino acids.

8 The characteristic mutations of the variants are silent in most cases (supplementary table).  
9 However, MuVs/Salamanca.ESP/24.19/ presents a L17P substitution and  
10 MuVs/NewJersey.USA/20.10/ has a P6L mutation.

11 An increase in the diversity of MuV SH variants and their derived haplotypes was observed  
12 throughout successive epidemic waves (figure 2). The MuVi/Sheffield.GBR/1.05/ variant was  
13 the only one identified in the 2005-2009 and 2010-2015 epidemic waves. However, in the last  
14 epidemic wave (2016-2019), several new circulating MuV variants were identified. The  
15 MuVs/Avila.ESP/11.16/ variant, was the first one, replacing the MuVi/Sheffield.GBR/1.05/  
16 variant, which became undetectable by mid-2016 and disappeared for one year. Meanwhile, two  
17 new MuV variants (MuVs/NewYork.USA/45.15/ and MuVs/Madrid.ESP/50.16/2) co-circulated  
18 with MuVs/Avila.ESP/11.16/. In the mid-2017, the MuVi/Sheffield.GBR/1.05/ variant  
19 reappeared, co-existing with the latter. During 2018 and 2019, the dominant variants,  
20 MuVs/NewYork.USA/45.15/ and MuVs/Avila.ESP/11.16/, were substituted by three new ones:  
21 MuVs/Avila.ESP/51.18/, MuVs/Salamanca.ESP/24.19/ and MuVs/New\_Jersey.USA/20.10/  
22 (figure 2).

23 A phylodynamic analysis was implemented in BEAST to estimate the time to the MRCA of  
24 each identified MuV variant clade. The estimated time of emergence of each clade was  
25 consistent with the epidemiological data (figure 3).

1 Entropy Shannon analysis revealed an entropy score along the SH gene of 6,83 for 2010-2015,  
2 while 4,72 for 2016-2019. The difference in entropy was more concentrated in some particular  
3 nucleotide positions in the second period, which correspond to the characteristic mutations of  
4 the new variants (C13A, C67T, T100C, A226T, T247C, and C248T) (figure 4).

5 Additional molecular tools based on sequencing of MuV genomic fragments including NCR  
6 were used to increase the phylogenetic resolution [12], to establish whether the new MuV  
7 variants evolved from those circulating previously or were introduced by importation events.  
8 With this purpose, a phylogenetic tree was derived using the concatenated N-P, M-F NCR and  
9 SH sequences from the first five cases of the emerging MuVs/Avila.ESP/11.16/ variant and the  
10 last six cases of the previously dominant MuVi/Sheffield.GBR/1.05/ variant (figure 5, panel A).  
11 Sequences from cases of the MuVs/Avila.ESP/11.16/ variant grouped in a separate/different  
12 branch of cases of the MuVi/Sheffield.GBR/1.05/ variant, suggesting an importation event. In  
13 order to study the re-emergence of the MuVi/Sheffield.GBR/1.05/ variant in 2017, a  
14 phylogenetic tree was derived using the concatenated N-P, M-F NCR and SH sequences from  
15 13 cases of the MuVi/Sheffield.GBR/1.05/ variant identified in 2017 and 2018, and  
16 simultaneous circulating variants. MuVi/Sheffield.GBR/1.05/ variant sequences grouped in a  
17 different clade from MuVs/Avila.ESP/11.16/ and MuVs/NewYork.USA/45.15/ (figure 5, panel  
18 B) suggesting importation. Finally, sequences of the MuVs/New\_Jersey.USA/20.10/ variant,  
19 which produced a big outbreak in Segovia in mid-2019 were analyzed. According to the  
20 topology of the phylogenetic tree (figure 5, panel C), the concatenated N-P, M-F NCR and SH  
21 sequences from cases of the MuVs/New\_Jersey.USA/20.10/ variant grouped in a clade.  
22 MuVi/Sheffield.GBR/1.05/ variant cases, which circulated earlier in 2019, were part of a  
23 different clade, but one sequence was at the base of the clade, suggesting that this variant  
24 evolved from existing one.

## 25 **Discussion**

26 Genotype G was the most frequently detected in Spain during the period of the study, as well as  
27 in other western countries and Japan [9] [11]. The MuVi/ Sheffield.GBR.1.05/ variant seemed

1 to be dominant, based on the sequences available in GenBank as previously described for the  
2 United States of America (USA) [26]. In Spain, MuV was able to circulate among the highly  
3 vaccinated population and generated successive epidemic waves [4][10][13]. It might be  
4 expected that periods of lower incidence could act as evolutionary bottlenecks in which some  
5 strains could disappear. The replacement of genotype H by the MuVi/Sheffield.GBR/1.05/  
6 variant of genotype G in 2005 is an example of this [11]. However, according to the SH gene  
7 analysis, the MuVi/Sheffield.GBR/1.05/ variant was able to remain the dominant strain  
8 throughout two subsequent epidemic waves (2005-2009, 2010-2015) with no apparent  
9 replacement. Additional molecular tools, based on sequencing of MuV genomic fragments  
10 including NCRs, were necessary to reveal the hidden strain replacement between the two  
11 epidemic waves, that remained unnoticed with the WHO recommended genotyping tool [12].  
12 However, in the course of the last epidemic wave (2016-2019), SH gene analysis was sufficient  
13 to reveal an increase of circulating variants of the G genotype mumps virus (figure 2). During  
14 this period, seven variants were identified, based on criteria detailed in the Materials and  
15 Methods, all of which belonged to the MuVi/Sheffield.GBR/1.05/ lineage. Haplotypes related to  
16 each variant grouped into the same clades of the ML phylogenetic tree (figure 1) and shared one  
17 or two specific mutations (supplementary table), suggesting that most of them were derived  
18 from each variant by genetic evolution. The number of mutations identified were concordant  
19 with the evolution rate previously estimated for the MuV SH gene ( $1.71 \times 10^{-3}$   
20 substitutions/site/year) [27].

21 The increase of new variants seems to be related to the emergence of new strains of MuV by  
22 local evolution over the time, which can eventually establish a sustained circulation. These  
23 variants subsequently generate derived haplotypes that are generally unable to spread through  
24 the population. However, one of them, MuVs/Madrid.ESP/50.16/2 succeeded in establish  
25 circulation as a new variant. Nevertheless, an importation event was probably the origin of the  
26 MuVs/Avila.ESP/11.16/ variant circulation in Spain, as suggested by the phylogenetic analysis  
27 of the concatenated SH, N-P and M-F NCR regions (figure 4, panel A). It could be the also the

1 case for MuVs/NewYork/45.15/ variant, which was circulating extensively during the previous  
2 weeks in other countries, such as the USA [26]. This variant is characterized by mutation  
3 C248T and was previously named as Sheffield-C248 T by Mac Nall *et al.*[26]. As suggested by  
4 the NCR analysis (Figure 4, panel B), the re-emergence of the MuVi/Sheffield.GBR/1.05/  
5 variant in 2017 was probably due to an importation event, rather than local evolution by  
6 reversion of the characteristic mutation from the co-circulating variants. In addition to  
7 importation events, local evolution was implied in the emergence of  
8 MuVs/New\_Jersey.USA/20.10/ variant and its derived haplotypes, responsible for causing an  
9 important outbreak in Segovia in 2019 (figure 4, panel C). The high number of mutations  
10 identified in nine haplotypes, many of them non synonymous (supplementary table), could not  
11 be explained by the local evolution of sequences, according to the evolution rate estimated for  
12 the MuV SH gene, and probably corresponded to distinct self-limited importation events. Two  
13 of them (MuVs/Guadalajara.ESP/22.19/ and MuVs/Soria.ESP/48.19/) grouped into variant  
14 clades because shared the specific characteristic mutations.

15 The topology of the phylogenetic tree of MuV variants and haplotypes circulating in Spain is  
16 consistent, with the temporal data of the sequences by the epidemiological week and year in  
17 which they were detected (figure 2), and shows their sequential emergence over the time. These  
18 results were confirmed, using the MCMC coalescent method implemented in BEAST, which  
19 estimated the times of emergence of the MRCA of each identified variant, (figure 3), which  
20 always occurred before the first week of detection of each variant.

21 Although the total Shannon entropy score obtained along the SH sequence was higher for 2010-  
22 2015 than for 2016-2019 epidemic wave, suggesting more genetic diversity in the first wave, an  
23 unique variant (MuVi/Sheffield.GBR/1.05/) was the predominant and most of the haplotypes  
24 detected were not successful. The total Shannon entropy score during the 2016-2019 epidemic  
25 wave was lower, but the difference in the entropy value was concentrated in six nucleotide  
26 positions (figure 4), concordant with the specific variant point mutations (C13A, C67T, T100C,  
27 A226T, T247C, and C248T), resulting in an increase of the number of circulating variants. Co-

1 circulation of different haplotypes has been previously described [26]. However, the number of  
2 circulating SH variants associated to characteristic mutations described here was not found in  
3 the USA, where C248T seemed to be the only one selected [26]. The longer period of study of  
4 the present work could account as an explanation for this difference. Surprisingly, we found a  
5 lower frequency (0,24% versus 1,79 %) of SH protein sequences with modified length[26], all  
6 three from different locations and years.

7 The co-circulation of several variants of one predominant lineage that emerged by local  
8 evolution, and from multiple independent introductions has previously been reported in the  
9 USA, from combining molecular tools based on the full genome and epidemiological analysis  
10 [28]. Full genome sequencing is replacing partial sequencing for molecular epidemiology  
11 studies of mumps [28][29][30] and other viral diseases. However, the recommendation of full  
12 genome sequencing as a global tool for laboratory surveillance of mumps is not feasible at  
13 present, due to the lack of availability of deep-sequencing technology in many countries.  
14 Consequently, current WHO protocols for mumps genotyping will continue to be used in the  
15 immediate future. In a previous study [12], we showed that additional markers based on the  
16 sequencing of genomic regions including NCRs, are required for the laboratory surveillance of  
17 mumps, in addition to the WHO protocols based on the SH sequence, following the emergence  
18 of a new dominant genotype. Other authors have used these new molecular markers to improve  
19 the resolution in molecular epidemiology studies [31], although they recommend the use of the  
20 complete genome to track chains of transmission [29].

21 Consequently, our results show the WHO recommended protocol for mumps genotyping based  
22 on the sequencing of the SH gene could not be discriminative enough to trace the circulation  
23 patterns of MuV in the years following the emergence of a new dominant genotype, as  
24 suggested in a previous work [12]. Under these circumstances, additional auxiliary markers as  
25 NCR sequences are needed. However, as genetic variability accumulated, SH sequence became  
26 discriminative enough for this purpose, although additional markers are still needed to establish  
27 the origin of the new variants as the result of local evolution or importation. Initially, genetic

1 variation seems to spread randomly through the SH sequence while the original imported  
2 variant persist as the dominant. After several years of continuous circulation variability seems to  
3 concentrate on some particular positions that seems to be fixed to became new variants able to  
4 establish circulation, until they are replaced by new ones. However, such mutations are  
5 synonymous in most cases. On the contrary, mutants in other positions fail to spread and are  
6 detected as sporadic haplotypes, even when some changes are not synonymous. This fact  
7 suggests that SH gene would not be the target for positive selection. The comparative study of  
8 the full genomes of SH MuV haplotypes that were or were not able to establish circulation,  
9 could allow to identify features which could eventually facilitate virus-spreading among highly-  
10 immunized populations.

#### 11 Study limitations

12 This study has two main limitations. The work made use of the samples received at the CNM  
13 through the specific surveillance mumps program and the Spanish MuV SH sequences available  
14 in GenBank. Although most Spanish provinces are represented in the dataset, they are not  
15 proportionally representative of their population. Fewer samples were received in 2012 and  
16 2013 than expected, given the incidence of mumps (figure 2), probably due to the coexistence  
17 of large measles outbreaks that placed great pressure on the work of the surveillance system.

18

## 1 References

- 2 1. Rubin S, Eckhaus M, Rennick LJ, Bamford CGG, Duprex WP. Molecular biology, pathogenesis  
3 and pathology of mumps virus. *J Pathol* [Internet]. John Wiley and Sons Ltd; **2015** [cited 2020  
4 Apr 23]; 235(2):242–252. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25229387>
- 5 2. Lam E, Rosen JB, Zucker JR. Mumps: An update on outbreaks, vaccine efficacy, and genomic  
6 diversity. *Clin Microbiol Rev.* **2020**; 33(2):1–16.
- 7 3. Situación de la Parotiditis en España [Internet]. 1982. Available from:  
8 [http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/fd-](http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/fd-enfermedades/fd-enfermedades-prevenibles-vacunacion/pdf_2017/Situacion_Parotiditis_ES_1982_2016.pdf)  
9 [enfermedades/fd-enfermedades-prevenibles-](http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/fd-enfermedades/fd-enfermedades-prevenibles-vacunacion/pdf_2017/Situacion_Parotiditis_ES_1982_2016.pdf)  
10 [vacunacion/pdf\\_2017/Situacion\\_Parotiditis\\_ES\\_1982\\_2016.pdf](http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/fd-enfermedades/fd-enfermedades-prevenibles-vacunacion/pdf_2017/Situacion_Parotiditis_ES_1982_2016.pdf)
- 11 4. López-Perea N, Masa-Calles J, Torres de Mier M de V, et al. Shift within age-groups of mumps  
12 incidence, hospitalizations and severe complications in a highly vaccinated population. Spain,  
13 1998–2014. *Vaccine.* **2017**; 35(34):4339–4345.
- 14 5. Ata Ur Rasheed M, Hickman CJ, McGrew M, et al. Decreased humoral immunity to mumps in  
15 young adults immunized with MMR vaccine in childhood. *Proc Natl Acad Sci U S A.* **2019**;  
16 116(38):19071–19076.
- 17 6. Nö Jd J, Teclé T, Samuelsson A. Mumps virus neutralizing antibodies do not protect against  
18 reinfection with a heterologous mumps virus genotype [Internet]. *Vaccine.* 2001. Available from:  
19 [www.elsevier.com/locate/vaccine](http://www.elsevier.com/locate/vaccine)
- 20 7. Šantak M, Lang-Balija M, Ivancic-Jelecki J, Košutić-Gulija T, Ljubin-Sternak S, Forcic D.  
21 Antigenic differences between vaccine and circulating wild-type mumps viruses decreases  
22 neutralization capacity of vaccine-induced antibodies. *Epidemiol Infect.* **2013**; 141(6):1298–1309.
- 23 8. Meeting NU. Weekly epidemiological record Relevé épidémiologique hebdomadaire. **2012**;  
24 27(22):217–224.
- 25 9. Jin L, Örvell C, Myers R, et al. Genomic diversity of mumps virus and global distribution of the  
26 12 genotypes. *Rev Med Virol.* **2015**; 25(2):85–101.
- 27 10. Cilla G, Montes M, Zapico MS, et al. Genetic characterization of historical epidemic mumps

- 1 viruses in northern Spain, 1987-1990. *Infect Genet Evol* [Internet]. Elsevier; **2014** [cited 2020  
2 Apr 23]; 28:5–10. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25176599>
- 3 11. Echevarría JE, Castellanos A, Sanz JC, et al. Circulation of mumps virus genotypes in Spain from  
4 1996 to 2007. *J Clin Microbiol*. **2010**; 48(4):1245–1254.
- 5 12. Gavilán AM, Fernández-García A, Rueda A, et al. Genomic non-coding regions reveal hidden  
6 patterns of mumps virus circulation in Spain, 2005 to 2015. *Eurosurveillance*. European Centre  
7 for Disease Prevention and Control (ECDC); **2018**; 23(15).
- 8 13. Barrabeig I, Antón A, Torner N, Pumarola T, Costa J, Domínguez À. Mumps: MMR vaccination  
9 and genetic diversity of mumps virus, 2007-2011 in Catalonia, Spain. *BMC Infect Dis*. *BMC*  
10 *Infectious Diseases*; **2019**; 19(1):1–11.
- 11 14. Royuela E, Castellanos A, Sánchez-Herrero C, Sanz JC, Ory F De, Echevarria JE. Mumps virus  
12 diagnosis and genotyping using a novel single RT-PCR. *J Clin Virol* [Internet]. Elsevier B.V.;  
13 **2011**; 52(4):359–362. Available from: <http://dx.doi.org/10.1016/j.jcv.2011.09.007>
- 14 15. Hall TA. BioEdit: A User-Friendly Biological Sequence Alignment Editor and Analysis Program  
15 for Windows 95/98/NT. *Nucleic Acids Symp Ser*. **1999**; 41:95–98.
- 16 16. Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7: Improvements  
17 in performance and usability. *Mol Biol Evol*. **2013**; 30(4):772–780.
- 18 17. Trifinopoulos J, Nguyen LT, Haeseler A von, Minh BQ. W-IQ-TREE: a fast online phylogenetic  
19 tool for maximum likelihood analysis. *Nucleic Acids Res*. **2016**; 44(W1):W232–W235.
- 20 18. Hoang DT, Chernomor O, Haeseler A von, Minh BQ, Vinh LS. UFBoot2: Improving the  
21 Ultrafast Bootstrap Approximation. *Molecular biology and evolution*. *Mol Biol Evol* [Internet].  
22 **2018**; 35(2):518–522. Available from: <http://www.iqtree.org>.
- 23 19. Kumar S, Stecher G, Tamura K. MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0  
24 for Bigger Datasets. *Mol Biol Evol*. **2016**; 33(7):1870–1874.
- 25 20. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. *J Mol*  
26 *Biol*. **1990**; 215(3):403–410.
- 27 21. Drummond AJ, Suchard MA, Xie D, Rambaut A. Bayesian phylogenetics with BEAUti and the

- 1 BEAST 1.7. *Mol Biol Evol.* **2012**; 29(8):1969–1973.
- 2 22. Rambaut A, Lam TT, Carvalho LM, Pybus OG. Exploring the temporal structure of  
3 heterochronous sequences using TempEst (formerly Path-O-Gen). *Virus Evol.* **2016**; 2(1):1–7.
- 4 23. Rambaut A, Drummond AJ, Xie D, Baele G, Suchard MA. Posterior summarization in Bayesian  
5 phylogenetics using Tracer 1.7. *Syst Biol.* **2018**; 67(5):901–904.
- 6 24. Rambaut. <http://tree.bio.ed.ac.uk/software/figtree/>.
- 7 25. No Title. Available from: <https://www.hiv.lanl.gov/content/sequence/ENTROPY/entropy.html>
- 8 26. McNall RJ, Wharton AK, Anderson R, et al. Genetic characterization of mumps viruses  
9 associated with the resurgence of mumps in the United States: 2015–2017. *Virus Res. Elsevier*  
10 *B.V.*; **2020**; 281.
- 11 27. Cui A, Rivaille P, Zhu Z, et al. Evolutionary analysis of mumps viruses of genotype F collected  
12 in mainland China in 2001–2015. *Sci Rep. Springer US*; **2017**; 7(1):1–7.
- 13 28. Wohl S, Metsky HC, Schaffner SF, et al. Combining genomics and epidemiology to track mumps  
14 virus transmission in the United States. *PLoS Biol.* **2020**; 18(2):e3000611.
- 15 29. Bodewes R, Reijnen L, Kerkhof J, et al. Molecular epidemiology of mumps viruses in the  
16 Netherlands, 2017–2019. *PLoS One. Public Library of Science*; 2020.
- 17 30. Magaña LC, Espinosa A, Marine RL, et al. Complete Genome Sequences of Mumps and Measles  
18 Virus Isolates from Three States in the United States. *Am Soc Microbiol [Internet]*. **2017** [cited  
19 2020 Jun 22]; . Available from: <https://doi.org/10.1128/genomeA>
- 20 31. Bodewes R, Rooijen K van, Cremer J, Veldhuijzen IK, Binnendijk R van. Optimizing molecular  
21 surveillance of mumps genotype G viruses. *Infect Genet Evol. Elsevier B.V.*; **2019**; 69:230–234.
- 22

## 1 **Figure legends**

2 **Figure 1. Phylogenetic tree of MuV SH sequences haplotypes.** Analysis employed the ML  
3 method in IQ-tree, using TNe as the evolutionary model. The MuV G genotype reference  
4 sequence (MuVi/Gloucester.GBR/32.96 [G], AF280799) was used as outgroup. Colored  
5 branches denote different variant clades and the earliest SH variant sequence of each variant is  
6 indicated by colored dots. An asterisk next to the name of the SH sequences indicates those with  
7  $\geq 4$  nt differences with respect to the MuVi/Sheffield.GBR/1.05/ variant. UltrafastBootstrap  
8 values  $> 80$  are shown.

9 **Figure 2. MuV genotype G SH variants with relevant circulation in Spain from 2007 to**  
10 **2019.**

11 **Figure 3. Time-scale tree of MuV SH haplotype and variant sequences.** The time of  
12 emergence of the MRCA is estimated in weeks, taking the last week of 2019 as the temporal  
13 reference. The week of each haplotype is included at the end of the name. The week of the  
14 MRCA of each variant is shown at the corresponding node. The MuV variant clades are  
15 identified by the previously used color code. Posterior probabilities  $\geq 0.8$  are shown as black  
16 spots.

17 **Figure 4. Shannon entropy differences between 2010-2015 and 2016-2019 epidemic waves**  
18 **MuV SH sequences alignments.** MuV SH sequences belonging to 2010-2015 epidemic waves  
19 were used as background (blue) and were represented at the positive Y-axis, whereas, sequences  
20 belonging to 2016-2019 were used as query (orange) and were represented at the negative Y-  
21 axis.

22 **Figure 5. Phylogenetic tree of MuV genome regions including N-P, M-F NCRs and SH**  
23 **concatenated sequences.** Analysis involved the ML method in W-IQ-TREE, using JC as  
24 evolutionary model. The MuV G genotype reference sequence (MuVi/Gloucester.GBR/32.96  
25 [G], AF280799) was used as outgroup. Panel A. Analysis to study the origin of the  
26 MuVs/Avila.ESP/11.16/ variant. Green spots correspond to the MuVs/Avila.ESP/11.16/ variant  
27 and red spots to the MuVi/Sheffield.GBR/1.05/ variant. Panel B. The study of the origin of the

1 re-emergence of the MuVi/Sheffield.GBR/1.05/ variant. Green dots correspond to the  
2 MuVs/Avila.ESP/11.16/ variant, grey dots to the MuVs/NewYork.USA/45.15/ variant and  
3 uncoloured spots correspond to the re-emerged MuVi/Sheffield.GBR/1.05/ variant. Panel C.  
4 Analysis to study the origin of the MuVs/New\_Jersey.USA/20.10/ variant. Pink dots correspond  
5 to the MuVs/New\_Jersey.USA/20.10/ variant, while derived haplotypes  
6 (MuVs/Segovia.ESP/39.19/2, MuVs/Segovia.ESP/39.19/12 and MuVs/Segovia.ESP/39.19/32)  
7 are indicated by empty circles. Red samples correspond to the MuVi/Sheffield.GBR/1.05/  
8 variant.

## 9 **Footnote page**

### 10 Conflict of interest

11 None declared.

### 12 Acknowledgements

13 We would like to thank Sara Ruiz and the Genomics Unit of the CNM-ISCIH for their technical  
14 assistance with sequencing. This work was supported by the “Instituto de Salud Carlos III”  
15 (PI15CIII/00023, PI19ICIII/0041). Ana M Gavilán was funded by CIBER de Epidemiología y  
16 Salud Pública (CIBERESP), ISCIH.

### 17 Authors' contributions


18 Ana María Gavilán: technical work, data analysis and writing as main author. Aurora  
19 Fernández-García and Juan Emilio Echevarría: design of the study, data analysis, and writing as  
20 main authors. Francisco Díez-Fuertes: technical bioinformatics, data analysis, drafting and  
21 revision of the manuscript. Noemi López-Perea: data analysis and drafting and revision of the  
22 manuscript. Ana M Castellanos: technical work. Juan Carlos Sanz, Silvia M Jiménez, Cristina  
23 Ruiz-Sopeña, and L. García-Comas: identification and confirmation of mumps cases and  
24 review and assistance in the editing the final version of the manuscript. J. Masa Calles, Mayte  
25 Pérez-Olmeda and Fernando de Ory: review and assistance in editing the final version of the  
26 manuscript.

### 27 Meeting where the information has previously been presented

28 23<sup>rd</sup> Annual Conference of the European Society for clinical virology. Increase in variability of  
29 mumps virus genotype G strains in Spain, 2008-2019. Manchester, 2021.

### 30 Corresponding author contact information


31 Aurora Fernández-García (aurorafg@isciii.es)



1  
2  
3

Figure 1  
150x233 mm (.25 x DPI)

1



2

3

4

5

Figure 2  
150x84 mm (.25 x DPI)

ACCEPTED MANUSCRIPT






Figure 3  
150x201 mm (.25 x DPI)

1  
2  
3  
4



**Figure 4**  
150x84 mm (.25 x DPI)



**Figure 5**  
150x101 mm (.25 x DPI)